Every tumor has a story.
In intrahepatic cholangiocarcinoma (iCCA), it may begin with FGFR2 fusion.
With next-generation sequencing, it’s now possible to identify clinically significant genomic alterations in ~50% of patients with iCCA, including the 10% to 16% of patients with FGFR2 fusions.1-6
Read about “The Importance of Molecular Profiling in Cholangiocarcinoma”
by Dr Ghassan Abou-Alfa.
Test all iCCA cases for clinically significant genomic alterations such as FGFR2 fusions.
Are you a patient or caregiver?
This site is intended for healthcare professionals. If you are a patient or caregiver interested in iCCA, click here to visit a website with information and resources designed for you.
FGFR, fibroblast growth factor receptor.
REFERENCES: 1. Lowery MA, Ptashkin R, Jordan E, et al. Clin Cancer Res. 2018;24(17):4154-4161. 2. Sia D, Losic B, Moeini A, et al. Nat Commun. 2015;6:6087. 3. Ross JS, Wang K, Gay L, et al. Oncologist. 2014;19(3):235-242. 4. Chun SY, Javle M. Cancer Control. 2017;24(3):1-7. 5. Farshidfar F, Zheng S, Gingras MC, et al. Cell Rep. 2017;18(11):2780-2794. 6. Graham RP, Barr Fritcher EG, Pestova E, et al. Hum Pathol. 2014;45(8):1630-1638.